Wegovy FDA Approval History: Timeline, Label Changes, and Safety Updates

Initial Approval: June 4, 2021

The FDA approved Wegovy on June 4, 2021, under BLA 215256 for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia 1. This made Wegovy the first GLP-1 receptor agonist approved specifically at the 2.4 mg dose for obesity.

Why 2.4 mg and Not the Diabetes Dose

Semaglutide was already on the market as Ozempic at doses up to 2.0 mg for type 2 diabetes. Novo Nordisk pursued a separate BLA rather than a supplemental application because the 2.4 mg dose, the target population, and the clinical development program were distinct. The FDA reviewed Wegovy through a standard review pathway with a 12-month review clock 2.

The STEP Program as the Regulatory Foundation

The approval rested primarily on the STEP clinical trial program. Four Phase 3 trials (STEP 1 through STEP 4) enrolled over 4,500 participants across varying populations. STEP-1 (N=1,961) demonstrated that semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks, compared with 2.4% in the placebo group 3. A third of participants lost 20% or more of their body weight. That magnitude of weight reduction from a pharmacotherapy alone had not been seen in any prior FDA-reviewed obesity drug application.

Approval Conditions and Labeling at Launch

The initial label carried a boxed warning about the risk of thyroid C-cell tumors, based on findings in rodents exposed to semaglutide. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The FDA also required Novo Nordisk to conduct several post-marketing studies, including a medullary thyroid carcinoma case registry 4.

The STEP-1 Trial in Detail

STEP-1 was a 68-week, randomized, double-blind, placebo-controlled trial that enrolled adults with BMI ≥30 (or ≥27 with at least one comorbidity) without diabetes 3. All participants received lifestyle intervention alongside drug or placebo. The results redefined clinical expectations for anti-obesity medications.

Primary and Secondary Endpoints

The co-primary endpoints were percentage change in body weight and the proportion of participants achieving ≥5% weight loss. Semaglutide met both: 86.4% of participants on drug achieved ≥5% weight loss versus 31.5% on placebo. The estimated treatment difference was -12.4 percentage points (95% CI: -13.4 to -11.5; P<0.001) 3.

Safety Profile From STEP-1

Gastrointestinal events were the most frequently reported adverse effects. Nausea occurred in 44.2% of semaglutide-treated participants versus 17.4% in the placebo group. Diarrhea affected 31.5% versus 15.9%. Most GI symptoms were mild to moderate and occurred during dose escalation. The discontinuation rate due to adverse events was 7.0% in the semaglutide group versus 3.1% with placebo 3.

Adolescent Indication: December 2022

On December 23, 2022, the FDA expanded Wegovy's indication to include adolescents aged 12 years and older with obesity (initial BMI at the 95th percentile or greater for age and sex) 5. This made Wegovy one of very few anti-obesity medications with a pediatric indication.

STEP TEENS Trial

The expansion was based on the STEP TEENS trial (N=201), a 68-week study in adolescents aged 12 to 17 with obesity. Participants treated with semaglutide 2.4 mg experienced a mean BMI reduction of 16.1% compared with a 0.6% increase in the placebo group 6. The safety profile in adolescents was consistent with what was observed in adults, with gastrointestinal side effects as the most common complaint.

Clinical Significance of the Pediatric Label

Before this approval, pharmacotherapy options for adolescent obesity were extremely limited. Dr. Aaron Kelly, co-director of the Center for Pediatric Obesity Medicine at the University of Minnesota, stated: "Having an effective pharmacological option for adolescents with obesity addresses a major unmet need. The degree of BMI reduction seen in STEP TEENS was unprecedented in pediatric obesity trials" 5.

Cardiovascular Risk Reduction: March 2024

The most significant label expansion came on March 8, 2024, when the FDA approved a new indication for Wegovy to reduce the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease who have either obesity or overweight 7. This was the first time any anti-obesity medication received a cardiovascular risk reduction indication.

The SELECT Trial

The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) randomized 17,604 adults aged 45 and older with established cardiovascular disease and BMI ≥27 (without diabetes) to semaglutide 2.4 mg or placebo 8. The primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.

SELECT Results

Over a mean follow-up of 39.8 months, the primary MACE endpoint occurred in 6.5% of participants receiving semaglutide versus 8.0% receiving placebo (hazard ratio 0.80; 95% CI: 0.72 to 0.90; P<0.001). That translates to a 20% relative risk reduction 8. The benefit was consistent across prespecified subgroups, including by baseline BMI, age, sex, and race.

Impact on Prescribing and Coverage

The cardiovascular indication changed the clinical and insurance field for Wegovy. Before SELECT, most commercial payers classified GLP-1 agonists for weight loss as lifestyle medications with limited or no coverage. The American Heart Association issued a statement noting: "The SELECT trial provides the strongest evidence to date that treating obesity can directly reduce cardiovascular events" 9. Several large payers began expanding formulary coverage following the label update 7.

Post-Market Safety Surveillance

Since approval, the FDA has monitored Wegovy through multiple pharmacovigilance channels, including the FDA Adverse Event Reporting System (FAERS), the Sentinel System, and required post-marketing studies from Novo Nordisk.

Thyroid C-Cell Tumor Monitoring

The boxed warning for thyroid C-cell tumors remains based on preclinical rodent data. No confirmed causal link between semaglutide and medullary thyroid carcinoma in humans has been established through post-market surveillance as of early 2026 10. The MTC registry required by the FDA continues to enroll cases and is expected to report results over a 15-year horizon.

Pancreatitis Signal

Reports of acute pancreatitis have appeared in FAERS data, consistent with the class-wide signal seen across GLP-1 receptor agonists. The Wegovy label lists pancreatitis as a warning and precaution, advising clinicians to discontinue semaglutide if pancreatitis is suspected and not to restart if confirmed 4. A 2023 population-based cohort study using Danish registry data found an adjusted incidence rate ratio of 1.6 (95% CI: 1.1 to 2.2) for acute pancreatitis among semaglutide users compared with non-users 11.

Gallbladder Events

Cholelithiasis and cholecystitis have been reported at higher rates in semaglutide-treated patients than in placebo groups across the STEP program. In STEP-1, gallbladder-related events occurred in 2.6% of semaglutide-treated participants versus 1.2% in the placebo arm 3. Rapid weight loss itself is a known risk factor for gallstone formation, making causality difficult to isolate.

Suicidal Ideation Investigation

In January 2024, the FDA completed an evaluation of post-market reports of suicidal ideation and behavior associated with GLP-1 receptor agonists, including semaglutide. The agency concluded that available evidence did not indicate a causal association between these drugs and suicidal thoughts or actions, but noted that monitoring would continue 12.

Supply Shortages and Resolution

Wegovy experienced significant supply constraints beginning in early 2022 and extending through portions of 2024. Novo Nordisk voluntarily restricted starter doses to manage supply for existing patients.

Shortage Timeline

The FDA placed Wegovy on its Drug Shortage Database in March 2022 after demand far exceeded manufacturing capacity. The 0.25 mg, 0.5 mg, and 1.0 mg starter doses were most affected, creating barriers for new patient starts. By Q4 2024, Novo Nordisk had expanded production at its facilities in Denmark and the United States, and the FDA removed all Wegovy dose strengths from the shortage list 13.

Compounding Implications

During the shortage, the FDA permitted 503A and 503B compounding pharmacies to produce copies of semaglutide under the agency's shortage-related compounding policies. As supply normalized, the FDA took enforcement actions against certain compounders and issued guidance clarifying that compounded semaglutide could no longer be distributed once the shortage was resolved 14.

Regulatory Comparisons: Wegovy vs. Other Anti-Obesity Agents

Wegovy's regulatory path has been distinct from other approved anti-obesity medications in both speed of label expansion and breadth of indications.

Comparison With Other GLP-1 Agents for Obesity

Tirzepatide (Zepbound), approved in November 2023, is the only other GLP-1-class agent with an obesity indication. Zepbound's approval was based on the SURMOUNT program and achieved numerically greater weight loss (up to 22.5% in SURMOUNT-1), but it does not yet carry a cardiovascular risk reduction indication 15. That distinction keeps Wegovy unique in its dual indication for weight management and MACE reduction.

Comparison With Pre-2021 Obesity Drugs

Prior to Wegovy, the most recently approved anti-obesity medication was liraglutide 3.0 mg (Saxenda) in 2014, also from Novo Nordisk. Saxenda produced approximately 5-8% mean weight loss. Phentermine-topiramate ER (Qsymia, 2012) and naltrexone-bupropion (Contrave, 2014) both produced weight loss in the 5-10% range. None of these agents has a cardiovascular outcomes indication 2.

Current Label and Prescribing Considerations

The most current Wegovy prescribing information reflects all three approved indications: adult obesity, adolescent obesity, and cardiovascular risk reduction. The dose-escalation schedule remains unchanged from the initial approval.

Dose Escalation Schedule

Patients begin at 0.25 mg weekly for 4 weeks, then increase to 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, and finally the maintenance dose of 2.4 mg weekly. The 16-week escalation is designed to reduce GI side effects. Clinicians may extend any dose-escalation step by an additional 4 weeks if a patient does not tolerate the increase 4.

Contraindications on Current Label

Wegovy remains contraindicated in patients with a personal or family history of MTC, MEN 2, or known hypersensitivity to semaglutide or any excipient. It should not be used in combination with other semaglutide-containing products or other GLP-1 receptor agonists 4.

Warnings and Precautions

The label includes warnings for pancreatitis, gallbladder disease, acute kidney injury (primarily from dehydration due to GI symptoms), hypoglycemia when used with insulin or sulfonylureas, diabetic retinopathy complications in patients with type 2 diabetes, heart rate increase (mean 1-4 beats per minute above placebo), and suicidal behavior or ideation (monitoring recommended) 4.

What May Come Next

Novo Nordisk has ongoing regulatory submissions and trials that could further modify the Wegovy label. A trial evaluating semaglutide in heart failure with preserved ejection fraction (STEP-HFpEF, N=529) showed significant improvements in symptoms, physical limitations, and body weight 16. Whether this leads to a formal indication remains to be determined. Additional post-marketing studies on long-term thyroid safety, weight maintenance beyond 2 years, and outcomes in broader populations (including patients with type 2 diabetes and obesity) are underway.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends semaglutide 2.4 mg as a first-line pharmacotherapy option for adults with BMI ≥30 or ≥27 with comorbidities, citing both efficacy and cardiovascular benefit data 17.